TGTX Q3 2024 Earnings — TG Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

TGTXTG Therapeutics, Inc.

$5B

Q3 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$84M-49.4% YoY

Gross Profit

$75M88.9% margin

Operating Income

$12M14.8% margin

Net Income

$4M4.6% margin

EPS (Diluted)

$0.02

QoQ Revenue Growth

+14.2%

Cash Flow

Operating Cash Flow

-$12M

Free Cash Flow

-$12M

Stock-Based Comp.

$12M

Balance Sheet

Total Assets

$586M

Total Liabilities

$394M

Stockholders' Equity

$192M

Cash & Equivalents

$196M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$84M	$166M	-49.4%
Gross Profit	$75M	$162M	-54.1%
Operating Income	$12M	$115M	-89.2%
Net Income	$4M	$114M	-96.6%

Revenue Segments

Product

$83M99%

Other Revenue

$315,0000%

Royalty

$229,0000%

License Revenue

$38,0000%